相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Tumour-intrinsic resistance to immune checkpoint blockade
Anusha Kalbasi et al.
NATURE REVIEWS IMMUNOLOGY (2020)
Epigenetic regulation of DNA repair genes and implications for tumor therapy
Markus Christmann et al.
MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH (2019)
N2M2 (NOA-20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma
Wolfgang Wick et al.
NEURO-ONCOLOGY (2019)
The landscape of the mesenchymal signature in brain tumours
Jinan Behnan et al.
BRAIN (2019)
Negative Co-stimulation Constrains T Cell Differentiation by Imposing Boundaries on Possible Cell States
Spencer C. Wei et al.
IMMUNITY (2019)
Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial
Patrick Y. Wen et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma
Kurt A. Schalper et al.
NATURE MEDICINE (2019)
Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma
Timothy F. Cloughesy et al.
NATURE MEDICINE (2019)
Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma
Junfei Zhao et al.
NATURE MEDICINE (2019)
The multiple mechanisms that regulate p53 activity and cell fate
Antonina Hafner et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2019)
The lncRNA TP73-AS1 is linked to aggressiveness in glioblastoma and promotes temozolomide resistance in glioblastoma cancer stem cells
Gal Mazor et al.
CELL DEATH & DISEASE (2019)
Temozolomide Induced Hypermutation in Glioma: Evolutionary Mechanisms and Therapeutic Opportunities
Paul Daniel et al.
FRONTIERS IN ONCOLOGY (2019)
Eribulin penetrates brain tumor tissue and prolongs survival of mice harboring intracerebral glioblastoma xenografts
Masamichi Takahashi et al.
CANCER SCIENCE (2019)
Second line treatment of recurrent glioblastoma with sunitinib: results of a phase II study and systematic review of literature
Salvatore Grisanti et al.
JOURNAL OF NEUROSURGICAL SCIENCES (2019)
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012-2016
Quinn T. Ostrom et al.
NEURO-ONCOLOGY (2019)
Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies
Spencer C. Wei et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Mutant p53 as a guardian of the cancer cell
Fiamma Mantovani et al.
CELL DEATH AND DIFFERENTIATION (2019)
Genetic, Epigenetic, and Immunologic Profiling of MMR-Deficient Relapsed Glioblastoma
Stefano Indraccolo et al.
CLINICAL CANCER RESEARCH (2019)
Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial
Giuseppe Lombardi et al.
LANCET ONCOLOGY (2019)
Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial
Derin B. Keskin et al.
NATURE (2019)
The molecular landscape of glioma in patients with Neurofibromatosis 1
Fulvio D'Angelo et al.
NATURE MEDICINE (2019)
Glioblastoma: Microenvironment and Niche Concept
Davide Schiffer et al.
CANCERS (2019)
PARP Inhibitors for Sensitization of Alkylation Chemotherapy in Glioblastoma: Impact of Blood-Brain Barrier and Molecular Heterogeneity
Shiv K. Gupta et al.
FRONTIERS IN ONCOLOGY (2019)
Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy
Patrick Y. Wen et al.
NEURO-ONCOLOGY (2018)
Molecular differences in IDH wildtype glioblastoma according to MGMT promoter methylation
Tobias Kessler et al.
NEURO-ONCOLOGY (2018)
High-Affinity GD2-Specific CAR T Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma Model
Sarah A. Richman et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Up-regulation of MSH6 is associated with temozolomide resistance in human glioblastoma
Quanye Sun et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2018)
Immune checkpoint therapy in liver cancer
Feng Xu et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2018)
Targetable Gene Fusions Associate With the IDH Wild-Type Astrocytic Lineage in Adult Gliomas
Sherise D. Ferguson et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2018)
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
S. L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Exploring Long Noncoding RNAs in Glioblastoma: Regulatory Mechanisms and Clinical Potentials
Tao Zeng et al.
INTERNATIONAL JOURNAL OF GENOMICS (2018)
Immune Microenvironment in Glioblastoma Subtypes
Zhihong Chen et al.
FRONTIERS IN IMMUNOLOGY (2018)
Phase II study of pembrolizumab or pembrolizumab plus bevacizumab for recurrent glioblastoma (rGBM) patients
David A. Reardon et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Phase-2 trial of palbociclib in adult patients with recurrent RB1-positive glioblastoma
Jennie W. Taylor et al.
JOURNAL OF NEURO-ONCOLOGY (2018)
Role of extracellular matrix and microenvironment in regulation of tumor growth and LAR-mediated invasion in glioblastoma
Yangjin Kim et al.
PLOS ONE (2018)
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Spencer C. Wei et al.
CANCER DISCOVERY (2018)
BRAF Inhibition in BRAFV600-Mutant Gliomas: Results From the VE-BASKET Study
Thomas Kaley et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Drug and disease signature integration identifies synergistic combinations in glioblastoma
Vasileios Stathias et al.
NATURE COMMUNICATIONS (2018)
Targeted Theranostic Nanoparticles for Brain Tumor Treatment
Maria Mendes et al.
PHARMACEUTICS (2018)
Immunotherapy of Hepatocellular Carcinoma: Facts and Hopes
Mercedes Inarrairaegui et al.
CLINICAL CANCER RESEARCH (2018)
Treatment of glioblastoma in adults
Wolfgang Wick et al.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2018)
Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy
A. Rotte et al.
ANNALS OF ONCOLOGY (2018)
Increased level of H19 long noncoding RNA promotes invasion, angiogenesis, and stemness of glioblastoma cells
Xiaochun Jiang et al.
JOURNAL OF NEUROSURGERY (2017)
Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma
Suzanne George et al.
IMMUNITY (2017)
Knockdown of SOX2OT inhibits the malignant biological behaviors of glioblastoma stem cells via up-regulating the expression of miR-194-5p and miR-122
Rui Su et al.
MOLECULAR CANCER (2017)
Distinctive Patterns of Transcription and RNA Processing for Human lincRNAs
Margarita Schlackow et al.
MOLECULAR CELL (2017)
Correlation of immune phenotype with IDH mutation in diffuse glioma
Anna Sophie Berghoff et al.
NEURO-ONCOLOGY (2017)
RANDOMIZED PHASE 3 STUDY EVALUATING THE EFFICACY AND SAFETY OF NIVOLUMAB VS BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA: CHECKMATE 143
D. A. Reardona et al.
NEURO-ONCOLOGY (2017)
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
S. S. Neelapu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Dung T. Le et al.
SCIENCE (2017)
T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition
Enfu Hui et al.
SCIENCE (2017)
T Cell Exhaustion in Glioblastoma: Intricacies of Immune Checkpoints
Reza Mirzaei et al.
TRENDS IN IMMUNOLOGY (2017)
HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma A Phase 1 Dose-Escalation Trial
Nabil Ahmed et al.
JAMA ONCOLOGY (2017)
Retrospective review of safety and efficacy of programmed cell death-1 inhibitors in refractory high grade gliomas
Samantha N. Reiss et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
The long non-coding RNA LOC441204 enhances cell growth in human glioma
Tzu-Kang Lin et al.
SCIENTIFIC REPORTS (2017)
A TCR-based Chimeric Antigen Receptor
Even Waiseng et al.
SCIENTIFIC REPORTS (2017)
Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade
Spencer C. Wei et al.
CELL (2017)
The Microenvironmental Landscape of Brain Tumors
Daniela F. Quail et al.
CANCER CELL (2017)
The movers and shapers in immune privilege of the CNS
Britta Engelhardt et al.
NATURE IMMUNOLOGY (2017)
Aberrant NEAT1 expression is associated with clinical outcome in high grade glioma patients
Chengbiao He et al.
APMIS (2016)
Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer
Kristin J. Lastwika et al.
CANCER RESEARCH (2016)
Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy
Weiyi Peng et al.
CANCER DISCOVERY (2016)
Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model
David A. Reardon et al.
CANCER IMMUNOLOGY RESEARCH (2016)
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
David N. Louis et al.
ACTA NEUROPATHOLOGICA (2016)
A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors
Xiaojun Liu et al.
CANCER RESEARCH (2016)
Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma
Michele Ceccarelli et al.
CELL (2016)
Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082)
Wolfgang Wick et al.
CLINICAL CANCER RESEARCH (2016)
RECIST 1.1-Update and clarification: From the RECIST committee
Lawrence H. Schwartz et al.
EUROPEAN JOURNAL OF CANCER (2016)
MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade
Peter J. R. Ebert et al.
IMMUNITY (2016)
Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial
Sarah B. Goldberg et al.
LANCET ONCOLOGY (2016)
DNA repair mechanisms and their clinical impact in glioblastoma
Helene Erasimus et al.
MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH (2016)
Clonal evolution of glioblastoma under therapy
Jiguang Wang et al.
NATURE GENETICS (2016)
Origin, fate and dynamics of macrophages at central nervous system interfaces
Tobias Goldmann et al.
NATURE IMMUNOLOGY (2016)
Recurrent MET fusion genes represent a drug target in pediatric glioblastoma
Sebastian Bender et al.
NATURE MEDICINE (2016)
In search of a target: PD-1 and PD-L1 profiling across glioma types
Anna S. Berghoff et al.
NEURO-ONCOLOGY (2016)
Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies
Sarah T. Garber et al.
NEURO-ONCOLOGY (2016)
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
Christine E. Brown et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells
Eugenia Zah et al.
CANCER IMMUNOLOGY RESEARCH (2016)
NPAS3 Regulates Transcription and Expression of VGF: Implications for Neurogenesis and Psychiatric Disorders
Dongxue Yang et al.
FRONTIERS IN MOLECULAR NEUROSCIENCE (2016)
Biomarkers in Cancer Immunotherapy
Ton N. Schumacher et al.
CANCER CELL (2015)
Temozolomide competes for P-glycoprotein and contributes to chemoresistance in glioblastoma cells
Jessian L. Munoz et al.
CANCER LETTERS (2015)
Knockdown of long non-coding RNA XIST exerts tumor-suppressive functions in human glioblastoma stem cells by up-regulating miR-152
Yilong Yao et al.
CANCER LETTERS (2015)
Data-Driven Phenotypic Dissection of AML Reveals Progenitor-like Cells that Correlate with Prognosis
Jacob H. Levine et al.
CELL (2015)
Detection, Characterization, and Inhibition of FGFR-TACC Fusions in IDH Wild-type Glioma
Anna Luisa Di Stefano et al.
CLINICAL CANCER RESEARCH (2015)
Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma
Christine E. Brown et al.
CLINICAL CANCER RESEARCH (2015)
Overcoming the blood-brain tumor barrier for effective glioblastoma treatment
O. van Tellingen et al.
DRUG RESISTANCE UPDATES (2015)
Salvage therapy with lomustine for temozolomide refractory recurrent anaplastic astrocytoma: a retrospective study
Marc C. Chamberlain
JOURNAL OF NEURO-ONCOLOGY (2015)
EGFR Amplified and Overexpressing Glioblastomas and Association With Better Response to Adjuvant Metronomic Temozolomide
Manuela Cominelli et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Impact of a New Fusion Receptor on PD-1-Mediated Immunosuppression in Adoptive T Cell Therapy
Sebastian Kobold et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
LRP1B deletion is associated with poor outcome for glioblastoma patients
E. Tabouret et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2015)
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
Jeffrey S. Weber et al.
LANCET ONCOLOGY (2015)
Structural and functional features of central nervous system lymphatic vessels
Antoine Louveau et al.
NATURE (2015)
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Stephen M. Ansell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
EGFR Amplified and Overexpressing Glioblastomas and Association With Better Response to Adjuvant Metronomic Temozolomide
Manuela Cominelli et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Impact of a New Fusion Receptor on PD-1-Mediated Immunosuppression in Adoptive T Cell Therapy
Sebastian Kobold et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Immunosuppressive mechanisms of malignant gliomas: parallels at non-CNS sites
Powell Perng et al.
FRONTIERS IN ONCOLOGY (2015)
A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K
Daniel J. Ma et al.
NEURO-ONCOLOGY (2015)
Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma
Kasthuri Kannan et al.
Oncotarget (2015)
Long non-coding RNA HOTAIR promotes glioblastoma cell cycle progression in an EZH2 dependent manner
Kailiang Zhang et al.
ONCOTARGET (2015)
Glioblastoma: Defining Tumor Niches
Dolores Hambardzumyan et al.
TRENDS IN CANCER (2015)
Hyaluronan: A simple polysaccharide with diverse biological functions
Kevin T. Dicker et al.
ACTA BIOMATERIALIA (2014)
CRNDE, a long non-coding RNA responsive to insulin/IGF signaling, regulates genes involved in central metabolism
Blake C. Ellis et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2014)
Intratumoral Heterogeneity of Genomic Imbalance in a Case of Epithelioid Glioblastoma with BRAF V600E Mutation
Sumihito Nobusawa et al.
BRAIN PATHOLOGY (2014)
Osteopontin-CD44 Signaling in the Glioma Perivascular Niche Enhances Cancer Stem Cell Phenotypes and Promotes Aggressive Tumor Growth
Alexander Pietras et al.
CELL STEM CELL (2014)
Analysis of DNA repair gene polymorphisms in glioblastoma
Irene Rodriguez-Hernandez et al.
GENE (2014)
MGMT testing-the challenges for biomarker-based glioma treatment
Wolfgang Wick et al.
NATURE REVIEWS NEUROLOGY (2014)
Immunotherapy advances for glioblastoma
David A. Reardon et al.
NEURO-ONCOLOGY (2014)
Molecular Heterogeneity of Glioblastoma and its Clinical Relevance
Katalin Eder et al.
PATHOLOGY & ONCOLOGY RESEARCH (2014)
Enhancing Chemotherapy Efficacy in Pten-Deficient Prostate Tumors by Activating the Senescence-Associated Antitumor Immunity
Alberto Toso et al.
CELL REPORTS (2014)
Exomics and immunogenics Bridging mutational load and immune checkpoints efficacy
Stephane Champiat et al.
ONCOIMMUNOLOGY (2014)
Cyclic RGD-Linked Polymeric Micelles for Targeted Delivery of Platinum Anticancer Drugs to Glioblastoma through the Blood-Brain Tumor Barrier
Yutaka Miura et al.
ACS NANO (2013)
Patterns of relapse in glioblastoma multiforme following concomitant chemoradiotherapy with temozolomide
J. Sherriff et al.
BRITISH JOURNAL OF RADIOLOGY (2013)
Double Minute Chromosomes in Glioblastoma Multiforme Are Revealed by Precise Reconstruction of Oncogenic Amplicons
J. Zachary Sanborn et al.
CANCER RESEARCH (2013)
The Somatic Genomic Landscape of Glioblastoma
Cameron W. Brennan et al.
CELL (2013)
The Definition of Primary and Secondary Glioblastoma
Hiroko Ohgaki et al.
CLINICAL CANCER RESEARCH (2013)
A survey of intragenic breakpoints in glioblastoma identifies a distinct subset associated with poor survival
Siyuan Zheng et al.
GENES & DEVELOPMENT (2013)
Structure and Interactions of the Human Programmed Cell Death 1 Receptor
Xiaoxiao Cheng et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
Net Clinical Benefit Analysis of Radiation Therapy Oncology Group 0525: A Phase III Trial Comparing Conventional Adjuvant Temozolomide With Dose-Intensive Temozolomide in Patients With Newly Diagnosed Glioblastoma
Terri S. Armstrong et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma
Tracy T. Batchelor et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Human T Cells Engineered To Express a Programmed Death 1/28 Costimulatory Retargeting Molecule Display Enhanced Antitumor Activity
Chen Ankri et al.
JOURNAL OF IMMUNOLOGY (2013)
Microenvironmental regulation of tumor progression and metastasis
Daniela F. Quail et al.
NATURE MEDICINE (2013)
BRAIN CANCER IN 2012 Molecular characterization leads the way
Roger Stupp et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2013)
Malignant astrocytomas of elderly patients lack favorable molecular markers: an analysis of the NOA-08 study collective
Benedikt Wiestler et al.
NEURO-ONCOLOGY (2013)
Which drug or drug delivery system can change clinical practice for brain tumor therapy?
Tali Siegal
NEURO-ONCOLOGY (2013)
Modern methods for delivery of drugs across the blood-brain barrier
Yan Chen et al.
ADVANCED DRUG DELIVERY REVIEWS (2012)
Positive conversion of negative signaling of CTLA4 potentiates antitumor efficacy of adoptive T-cell therapy in murine tumor models
Jae Hun Shin et al.
BLOOD (2012)
TGFβ signaling plays a critical role in promoting alternative macrophage activation
Dapeng Gong et al.
BMC IMMUNOLOGY (2012)
Molecular characteristics of glioblastoma with 1p/19q co-deletion
Masahiro Mizoguchi et al.
BRAIN TUMOR PATHOLOGY (2012)
Imaging Tumor-Stroma Interactions during Chemotherapy Reveals Contributions of the Microenvironment to Resistance
Elizabeth S. Nakasone et al.
CANCER CELL (2012)
The Quest for Self-Identity: Not All Cancer Stem Cells Are the Same
Anita B. Hjelmeland et al.
CLINICAL CANCER RESEARCH (2012)
IDO Expression in Brain Tumors Increases the Recruitment of Regulatory T Cells and Negatively Impacts Survival
Derek A. Wainwright et al.
CLINICAL CANCER RESEARCH (2012)
NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: A randomised phase III trial of a novel treatment modality
Roger Stupp et al.
EUROPEAN JOURNAL OF CANCER (2012)
STAR RNA-binding protein Quaking suppresses cancer via stabilization of specific miRNA
An-Jou Chen et al.
GENES & DEVELOPMENT (2012)
Emerging insights into the molecular and cellular basis of glioblastoma
Gavin P. Dunn et al.
GENES & DEVELOPMENT (2012)
Predictive impact of MGMT promoter methylation in glioblastoma of the elderly
Guido Reifenberger et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
Interstitial guidance of cancer invasion
Pavlo G. Gritsenko et al.
JOURNAL OF PATHOLOGY (2012)
Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial
Annika Malmstrom et al.
LANCET ONCOLOGY (2012)
Tumor PD-L1 co-stimulates primary human CD8+ cytotoxic T cells modified to express a PD1:CD28 chimeric receptor
Megan E. Prosser et al.
MOLECULAR IMMUNOLOGY (2012)
Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma
Jeremy Schwartzentruber et al.
NATURE (2012)
Transforming Fusions of FGFR and TACC Genes in Human Glioblastoma
Devendra Singh et al.
SCIENCE (2012)
NPAS3 Demonstrates Features of a Tumor Suppressive Role in Driving the Progression of Astrocytomas
Frederico Moreira et al.
AMERICAN JOURNAL OF PATHOLOGY (2011)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Pathway Analysis of Glioblastoma Tissue after Preoperative Treatment with the EGFR Tyrosine Kinase Inhibitor Gefitinib-A Phase II Trial
Monika E. Hegi et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma?
Nanne K. Kloosterhof et al.
LANCET ONCOLOGY (2011)
The Three-Layer Concentric Model of Glioblastoma: Cancer Stem Cells, Microenvironmental Regulation, and Therapeutic Implications
Luca Persano et al.
THESCIENTIFICWORLDJOURNAL (2011)
Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomide
K. A. van Nifterik et al.
BRITISH JOURNAL OF CANCER (2010)
Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1
Roel G. W. Verhaak et al.
CANCER CELL (2010)
The PD-1 pathway in tolerance and autoimmunity
Loise M. Francisco et al.
IMMUNOLOGICAL REVIEWS (2010)
Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
Julie R. Brahmer et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Salvage therapy with single agent bevacizumab for recurrent glioblastoma
Marc C. Chamberlain et al.
JOURNAL OF NEURO-ONCOLOGY (2010)
Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2
Richard A. Morgan et al.
MOLECULAR THERAPY (2010)
Systemic immune suppression in glioblastoma: the interplay between CD14+HLA-DRlo/neg monocytes, tumor factors, and dexamethasone
Michael P. Gustafson et al.
NEURO-ONCOLOGY (2010)
The blood-brain barrier in brain homeostasis and neurological diseases
Nicolas Weiss et al.
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES (2009)
MSH6 Mutations Arise in Glioblastomas during Temozolomide Therapy and Mediate Temozolomide Resistance
Stephen Yip et al.
CLINICAL CANCER RESEARCH (2009)
T-cell receptor binding affinities and kinetics: impact on T-cell activity and specificity
Jennifer D. Stone et al.
IMMUNOLOGY (2009)
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Henry S. Friedman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
Roger Stupp et al.
LANCET ONCOLOGY (2009)
Association of reactive oxygen species levels and radioresistance in cancer stem cells
Maximilian Diehn et al.
NATURE (2009)
Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab
Eudocia C. Quant et al.
NEURO-ONCOLOGY (2009)
Promoter Methylation and Polymorphisms of the MGMT Gene in Glioblastomas: A Population-Based Study
Izabela Zawlik et al.
NEUROEPIDEMIOLOGY (2009)
Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1α
Shimin Zhao et al.
SCIENCE (2009)
The interface between glial progenitors and gliomas
Peter Canoll et al.
ACTA NEUROPATHOLOGICA (2008)
Extracellular matrix of the central nervous system: from neglect to challenge
Dieter R. Zimmermann et al.
HISTOCHEMISTRY AND CELL BIOLOGY (2008)
Survival of the fittest: Cancer stem cells in therapeutic resistance and angiogenesis
Christine E. Eyler et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
L. Chin et al.
NATURE (2008)
An integrated genomic analysis of human glioblastoma Multiforme
D. Williams Parsons et al.
SCIENCE (2008)
Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment
Daniel P. Cahill et al.
CLINICAL CANCER RESEARCH (2007)
Patterns of somatic mutation in human cancer genomes
Christopher Greenman et al.
NATURE (2007)
Formation of non-random extrachromosomal elements during development, differentiation and oncogenesis
Fabien Kuttler et al.
SEMINARS IN CANCER BIOLOGY (2007)
A perivascular niche for brain tumor stem cells
Christopher Calabrese et al.
CANCER CELL (2007)
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response
Shideng Bao et al.
NATURE (2006)
Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells
Peter E. Fecci et al.
CLINICAL CANCER RESEARCH (2006)
Vascular endothelial growth factor directly inhibits primitive neural stem cell survival but promotes definitive neural stem cell survival
Tamaki Wada et al.
JOURNAL OF NEUROSCIENCE (2006)
A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy
C Hunter et al.
CANCER RESEARCH (2006)
Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma.
PE Fecci et al.
CANCER RESEARCH (2006)
Inhibition of poly (ADP-ribose) polymerase activates ATM which is required for subsequent homologous recombination repair
HE Bryant et al.
NUCLEIC ACIDS RESEARCH (2006)
Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: Tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01
AB Lassman et al.
CLINICAL CANCER RESEARCH (2005)
Poly(ADP-ribose) polymerase (PARP-1) in homologous recombination and as a target for cancer therapy
T Helleday et al.
CELL CYCLE (2005)
Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme
SM Chang et al.
INVESTIGATIONAL NEW DRUGS (2005)
MGMT gene silencing and benefit from temozolomide in glioblastoma
ME Hegi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Preoperative and intraoperative diffusion tensor imaging-based fiber tracking in glioma surgery
C Nimsky et al.
NEUROSURGERY (2005)
Vaso-occlusive and prothrombotic mechanisms associated with tumor hypoxia, necrosis, and accelerated growth in glioblastoma
DJ Brat et al.
LABORATORY INVESTIGATION (2004)
Pseudopalisades in glioblastoma are hypoxic, express extracellular matrix proteases, and are formed by an actively migrating cell population
DJ Brat et al.
CANCER RESEARCH (2004)
CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas
MF Paz et al.
CLINICAL CANCER RESEARCH (2004)
Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase
C Uyttenhove et al.
NATURE MEDICINE (2003)
Expression of extracellular matrix components in a highly infiltrative in vivo glioma model
R Mahesparan et al.
ACTA NEUROPATHOLOGICA (2003)
CD44: From adhesion molecules to signalling regulators
H Ponta et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2003)
The interaction properties of costimulatory molecules revisited
AV Collins et al.
IMMUNITY (2002)
Analysis of homozygous deletion of the p16 gene and correlation with survival in patients with glioblastoma multiforme
T Kamiryo et al.
JOURNAL OF NEUROSURGERY (2002)
Hyaluronate receptors mediating glioma cell migration and proliferation
Y Akiyama et al.
JOURNAL OF NEURO-ONCOLOGY (2001)
Anti-inflammatory cytokines: Expression and action in the brain
L Vitkovic et al.
NEUROIMMUNOMODULATION (2001)
Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents
M Esteller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Extracellular matrix and the brain: components and function
U Novak et al.
JOURNAL OF CLINICAL NEUROSCIENCE (2000)
分享论文
